ALLANDER BIOTECHNOLOGIES, INC.

AURORA, CO · Founded 2023 · Biotech · Private

Proprietary biologic therapeutic for preventing and treating radiation-induced oral mucositis, administered as an oral gel rinse

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: AURORA, CO
Founded: 2023
Latest Form D: $1M, Oct 2023
Total capital: $6.9M

Federal grants: $5.9M; 7 awards · 2017–2025; Rank in peer group#72 of 514
Private capital raised: $1M; 1 Form D · last Oct 2023; 37 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Sep 2025Federal grantHealth and Human S · Phase II · First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients$1.2M
Oct 2023Private capital raisedForm D · SEC · 1st filing$1M
Aug 2021Federal grantHealth and Human S · Phase II · Proprietary drug to treat radiodermatitis$523K
Sep 2020Federal grantHealth and Human S · Phase II · Proprietary drug to treat radiodermatitis$1.2M
Jul 2019Federal grantHealth and Human S · Phase II · Proprietary biologic treatment to heal skin wounds$715K
Sep 2018Federal grantHealth and Human S · Phase II · Proprietary biologic treatment to heal skin wounds$796K
Aug 2018Federal grantHealth and Human S · Phase II · Topical proprietary biologic to treat oral mucositis$703K

Show 1 earlier federal award

Sep 2017Federal grantHealth and Human S · Phase II · Topical proprietary biologic to treat oral mucositis$797K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

73months

from ALLANDER BIOTECHNOLOGIES, INC.’s first federal award to its first private round.

First federal award · Sep 2017: Health and Human S · $797K
First Form D · Oct 2023: $1M · 1st Form D
Awards before first raise: 6 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#72 · top 14%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Bing ZhaoDirectorNamed in SEC Form D filings
XiaoJing WangExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

TOPAZ BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
ACCURIUS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Goldilocks Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
WinSanTor, Inc.Similar federal contract value in Biotech · null in contracts
Kioga Inc.Similar federal contract value in Biotech · null in contracts
ZENA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.